These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 544295)

  • 21. Activated clotting factors in factor IX concentrates.
    Hultin MB
    Blood; 1979 Nov; 54(5):1028-38. PubMed ID: 497395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
    Chan AK; Berry LR; Monagle PT; Andrew M
    Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The resistance of activated partial thromboplastin time to heparin infusion during hemodialysis].
    Camici M; Sagripanti A; Barsotti G; Baicchi U; Evangelisti L; Morelli E; Giovannetti S
    Minerva Med; 1995 Sep; 86(9):353-5. PubMed ID: 7501225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin.
    Andrew M; Schmidt B; Mitchell L; Paes B; Ofosu F
    Thromb Haemost; 1990 Feb; 63(1):27-30. PubMed ID: 2339359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies on the thrombogenic activities in two prothrombin complex concentrates.
    Hedner U; Nilsson IM; Bergentz SE
    Thromb Haemost; 1979 Oct; 42(3):1022-32. PubMed ID: 315624
    [No Abstract]   [Full Text] [Related]  

  • 26. [Dynamics of thrombin-antithrombin-III complex (TAT-III) and prothrombin fragments F1 + 2 during labour with and without aprotinin administration].
    Kühnert M; Stein W; Woernle F; Tekesin I; Hellmeyer L; Schmidt S
    Z Geburtshilfe Neonatol; 2004 Jun; 208(3):98-109. PubMed ID: 15229817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models.
    Prowse CV; Williams AE
    Thromb Haemost; 1980 Oct; 44(2):81-6. PubMed ID: 6779401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo.
    White GC; Roberts HR; Kingdon HS; Lundblad RL
    Blood; 1977 Feb; 49(2):159-70. PubMed ID: 12845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of the KC10 semi-automatic modular clot detection device].
    Crespo B; Ankri A; Lesty C
    Nouv Rev Fr Hematol (1978); 1983; 25(2):113-21. PubMed ID: 6408609
    [No Abstract]   [Full Text] [Related]  

  • 30. Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates.
    Dusel CH; Grundmann C; Eich S; Seitz R; König H
    Blood Coagul Fibrinolysis; 2004 Jul; 15(5):405-11. PubMed ID: 15205589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction?
    Ben-Ari Z; Osman E; Hutton RA; Burroughs AK
    Am J Gastroenterol; 1999 Oct; 94(10):2977-82. PubMed ID: 10520855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pediatric patients with congenital heart disease: thrombin generation measured by calibrated automated thrombography.
    Rosenkranz A; Koestenberger M; Novak M; Cvirn G; Leschnik B; Gamillscheg A; Beitzke A; Muntean W
    Blood Coagul Fibrinolysis; 2008 Jul; 19(5):389-93. PubMed ID: 18600087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A microtitre plate test for assessment of in-vitro thrombogenicity in factor IX concentrates using a chromogenic substrate.
    Farrugia A; Oates A; Spiers D; Young I; Herrington R
    Thromb Res; 1989 Jan; 53(2):191-6. PubMed ID: 2922707
    [No Abstract]   [Full Text] [Related]  

  • 34. In vitro tests of the potential thrombogenicity of factor IX concentrates: inhibition and characterisation studies of NAPTT, TGt50 and PF3 moieties.
    Prowse C; Pepper DS
    Thromb Res; 1980 Dec 1-15; 20(5-6):491-8. PubMed ID: 7233381
    [No Abstract]   [Full Text] [Related]  

  • 35. Thrombogenicity testing of central venous catheters in vitro.
    Böswald M; Lugauer S; Bechert T; Greil J; Regenfus A; Guggenbichler JP
    Infection; 1999; 27 Suppl 1():S30-3. PubMed ID: 10379440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of plasma for fractionation--does it matter?
    Smith JK
    Transfus Sci; 1994 Dec; 15(4):343-50. PubMed ID: 10155552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on the effect of heat treatment on the thrombogenicity of factor IX concentrates in dogs.
    Littlewood JD; Dawes J; Smith JK; Feldman PA; Haddon ME; McQuillan TA; Foster PR; Ferguson J; Prowse CV
    Br J Haematol; 1987 Apr; 65(4):463-8. PubMed ID: 3580303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The thrombogenicity of prothrombin complex concentrates: I. The relationship between in vitro characteristics and in vivo thrombogenicity in rabbits.
    Giles AR; Johnston M; Hoogendoorn H; Blajchman M; Hirsh J
    Thromb Res; 1980 Feb 1-15; 17(3-4):353-66. PubMed ID: 6768160
    [No Abstract]   [Full Text] [Related]  

  • 39. In vitro thrombogenicity tests of factor IX concentrates.
    Pepper DS; Banhegyi D; Howie A; Cash JD
    Br J Haematol; 1977 Aug; 36(4):573-83. PubMed ID: 889720
    [No Abstract]   [Full Text] [Related]  

  • 40. Thrombogenicity of prothrombin complex concentrates.
    Köhler M
    Thromb Res; 1999 Aug; 95(4 Suppl 1):S13-7. PubMed ID: 10499904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.